{"id":22302,"date":"2014-05-15T06:21:08","date_gmt":"2014-05-15T10:21:08","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=22302"},"modified":"2014-05-15T06:21:08","modified_gmt":"2014-05-15T10:21:08","slug":"novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302","title":{"rendered":"Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 05\/15\/2014 (wallstreetpr) \u2013 The Switzerland-based drug giant <b>Novartis AG (ADR) (NYSE:NVS)<\/b> has reached another milestone with the latest patent litigation settlement in the U.S. \u00a0The company reached a settlement with the U.S. subsidiary of Sun Pharmaceutical Industries.<\/p>\n<p style=\"text-align: justify;\">\u00a0The agreement touches on the development of a generic version of Gleevec, a patented prescription drug whose patent protection expires in 2019.\u00a0 The settlement permits the subsidiary of Sun Pharmaceutical to develop and market a generic version of Gleevec.<\/p>\n<p style=\"text-align: justify;\">The generic version of Gleevec development by Sun Pharmaceutical\u2019s U.S. subsidiary could hit the shelves in February 2016. It is reported that the U.S. subsidiary of Sun Pharmaceutical has already secured a tentative approval from the U.S. Food and Drug Administration for its generic version of Gleevec. However, the finer details of the patent permitting and settlement are confidential.<\/p>\n<p style=\"text-align: justify;\">The latest patent settlement serves more than just ironing out the conflict between Novartis AG (ADR) (NYSE:NVS) and the Sun Pharmaceutical. It validates Novartis\u2019 patent for Gleevec and also allows Sun Pharmaceutical\u2019s subsidiary to bring a generic version of the drug to market without fear of costly legal action against it.<\/p>\n<p style=\"text-align: justify;\"><b>Novartis has it both ways<\/b><\/p>\n<p style=\"text-align: justify;\">Novartis AG (ADR) (NYSE:NVS) provides both patented and generic pharmaceuticals. The company develops and commercializes high-quality generic drugs through Sandoz, a division of the Switzerland drug giant. The company&#8217;s ability to develop branded and generic drugs have enabled it to provide a wide range of treatment options to patients. The strategy also supports its business by attracting higher revenue.<\/p>\n<p style=\"text-align: justify;\"><b>Drug development collaboration <\/b><\/p>\n<p style=\"text-align: justify;\">Novartis AG (ADR) (NYSE:NVS) announced teaming up with French drug company Servier towards the development and marketing of novel cancer drug candidate that targets apoptosis. The collaboration with Servier is the latest drug development tie-up that Novartis AG (ADR) (NYSE:NVS) has entered. Last month the company agreed to trade $20 billion in assets with <strong>GlaxoSmithKline PLC (ADR) (NYSE:GSK)<\/strong>. The transaction was such that Novartis would swap its vaccine business with GSK\u2019s cancer drug business. The two giant drug makers also agreed to join forces in the development of consumer healthcare products through a joint venture.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 05\/15\/2014 (wallstreetpr) \u2013 The Switzerland-based drug giant Novartis AG (ADR) (NYSE:NVS) has reached another milestone with the latest patent litigation settlement in the [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":22312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1734,1740,1735,1464],"stock_ticker":[],"class_list":["post-22302","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-glaxosmithkline-plc-adr-nysegsk","tag-novartis-ag-adr-nysenvs","tag-nysegsk","tag-nysenvs","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 05\/15\/2014 (wallstreetpr) \u2013 The Switzerland-based drug giant Novartis AG (ADR) (NYSE:NVS) has reached another milestone with the latest patent litigation settlement in the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-05-15T10:21:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Novartis-AG.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"457\" \/>\n\t<meta property=\"og:image:height\" content=\"110\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical\",\"datePublished\":\"2014-05-15T10:21:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302\"},\"wordCount\":375,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Novartis-AG.jpg\",\"keywords\":[\"GlaxoSmithKline plc (ADR) (NYSE:GSK)\",\"Novartis AG (ADR) (NYSE:NVS)\",\"NYSE:GSK\",\"NYSE:NVS\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302\",\"name\":\"Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Novartis-AG.jpg\",\"datePublished\":\"2014-05-15T10:21:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Novartis-AG.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Novartis-AG.jpg\",\"width\":457,\"height\":110},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302","og_locale":"en_US","og_type":"article","og_title":"Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical - Wall Street PR","og_description":"Boston, MA 05\/15\/2014 (wallstreetpr) \u2013 The Switzerland-based drug giant Novartis AG (ADR) (NYSE:NVS) has reached another milestone with the latest patent litigation settlement in the [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-05-15T10:21:08+00:00","og_image":[{"width":457,"height":110,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Novartis-AG.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical","datePublished":"2014-05-15T10:21:08+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302"},"wordCount":375,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Novartis-AG.jpg","keywords":["GlaxoSmithKline plc (ADR) (NYSE:GSK)","Novartis AG (ADR) (NYSE:NVS)","NYSE:GSK","NYSE:NVS"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302","url":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302","name":"Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Novartis-AG.jpg","datePublished":"2014-05-15T10:21:08+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Novartis-AG.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Novartis-AG.jpg","width":457,"height":110},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novartis-ag-adr-nysenvs-settles-patent-litigation-with-the-u-s-subsidiary-of-sun-pharmaceutical-22302#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/22302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=22302"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/22302\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/22312"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=22302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=22302"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=22302"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=22302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}